Plamotamab (XmAb-13676), a human bispecific antibody (bsAb) targeting CD3 and CD20, recruits cytotoxic T cells to eliminate CD20-expressing tumor cells. It demonstrates mild hematologic reaction (MR) and effectively induces tumor regression in vivo [1] [2].
CAS Number:
[2138442-31-4]
Target:
Integrin|||Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
